Feed LEGN
LE

Legend Biotech

LEGN · NASDAQ

$18.64 -4.31% (-$0.84)
1M -8.49%
Market Cap $3.55B
P/E Ratio -
Div. Yield -
ROE 8.70%
Piotroski F-Score Weak
3/9
Valuation
66 /100
Fair
P/B 2.89x
P/S 2.79x
P/FFO N/A
Growth
96 /100
Growing
Book val. growth 10.42%
Rev. growth 106.41%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 7.21%
Op. margin 4.42%
FCF margin 20.10%
Quality
9 /100
Poor
ROE 8.70%
ROA 5.23%
Asset turnover 0.73x
Debt
69 /100
Low
Current ratio 3.04x
Int. coverage -2.59x
Debt/Equity 0.23x
Stability
20 /100
Unstable
Rev. volatility 40.90%
EPS volatility 66.06%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o LEGN
Online

O podjetju

Legend Biotech Corporation (LEGN) is a global biotechnology company focused on developing and commercializing innovative therapeutic products in the field of hematology and oncology. The company is dedicated to researching new therapies for patients with leukemia and lymphoma, and its portfolio includes several potential drugs that have undergone clinical trials. Legend Biotech prioritizes high-quality research and development, collaborates with academic institutions and pharmaceutical partners, and stays abreast of the latest innovations in oncology. With increasing awareness of hematological disorders and a growing interest in new treatment modalities, investing in Legend Biotech Corporation (LEGN) shares may represent an interesting opportunity for investors interested in the biotechnology sector and seeking a company focused on innovative therapeutic products.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Alan S. Bash

Employees

3,200

Headquarters

Somerset

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

59d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.